Bicycle Therapeutics (BCYC) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immuneering (IMRX) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 36.8% versus a loss of 53.9%. Over five years, IMRX leads with a -84.5% price change compared with -93.6% for BCYC. Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $242.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | IMRX |
|---|---|---|
| Share price | $3.81 | $3.74 |
| Market cap | $266.67M | $241.97M |
| 1-day change | +2.14% | -3.11% |
| YTD return | -46.19% | -41.34% |
| 1-year return | -53.87% | -36.82% |
| 5-year return | -93.57% | -84.47% |
| EPS (TTM) | $-2.73 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.16 | $8.48 |
| 52-week low | $3.33 | $3.60 |
| Distance from 52-week high | -58.40% | -55.90% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +149.34% | +359.09% |
| Average volume | 391.03K | 694.54K |
| Shares outstanding | 50.55M | 64.70M |
| Employees | 288 | 57 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMRX has outperformed BCYC by 17.0 percentage points over the past year.
- The two companies sit in different sectors: Bicycle Therapeutics in Healthcare and Immuneering in Health Care.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Healthcare · Biotechnology · 288 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
BCYC vs IMRX FAQ
Which is bigger, Bicycle Therapeutics or Immuneering?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $241.97M for Immuneering (IMRX).
Which stock has performed better over the past year, BCYC or IMRX?
IMRX returned -36.82% over the past 12 months, compared with -53.87% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Immuneering in the same industry?
No. Bicycle Therapeutics is in the Healthcare sector, while Immuneering is in Health Care.